Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TLR2 | O60603 | 5/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.46 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17615128 | 1.00 | KMT2A (0.58) | KMT2ATLR2MDM2TLR1MDM4 | |
| SCHEMBL16192928 | 0.93 | KMT2A (0.50) | KMT2ATLR2MDM2TLR1 | |
| SCHEMBL13938802 | 0.88 | KMT2A (0.59) | KMT2ATLR2MDM2TLR1 | |
| SCHEMBL19919108 | 0.87 | TLR2 (0.64) | KMT2ATLR2 | |
| SCHEMBL26156344 | 0.87 | KMT2A (0.62) | KMT2ATLR2MDM2MDM4TP53 | |
| SCHEMBL22854294 | 0.87 | TLR2 (0.54) | KMT2ATLR2MDM4TP53 | |
| SCHEMBL16925664 | 0.87 | KMT2A (0.64) | KMT2ATLR2MDM2MDM4TP53 | |
| SCHEMBL26156345 | 0.87 | KMT2A (0.64) | KMT2ATLR2MDM2MDM4TP53 | |
| SCHEMBL13311713 | 0.87 | TLR2 (0.54) | KMT2ATLR2MDM2MDM4TP53 | |
| SCHEMBL14064933 | 0.87 | TLR2 (0.54) | KMT2ATLR2MDM2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12042542-B2 | Synthetic antibody mimetic compounds (SYAMS) targeting cancer, especially prostate cancer | YALE UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20220111060-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | UNIV YALE (US) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220111060-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | FCGR1A, CD47, FCGR3B | KMT2A 577/4885TLR2 109/4885MDM2 2541/4885 |
| US-12042542-B2 | Synthetic antibody mimetic compounds (SYAMS) targeting cancer, especially prostate cancer | CD47, FCGR1A, FCGR2A | KMT2A 718/4885TLR2 157/4885MDM2 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.